Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Akebia Therapeutics's Enterprise Value is €251.9 Mil.
Akebia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-33.4 Mil. Therefore, Akebia Therapeutics's EV-to-EBIT ratio for today is -7.53.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Akebia Therapeutics's Enterprise Value is €251.9 Mil.
Akebia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €1.3 Mil. Therefore, Akebia Therapeutics's EV-to-EBITDA ratio for today is 192.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Akebia Therapeutics's Enterprise Value is €251.9 Mil.
Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €173.0 Mil. Therefore, Akebia Therapeutics's EV-to-Revenue ratio for today is 1.46.
Akebia Therapeutics Enterprise Value Historical Data
The historical data trend for Akebia Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akebia Therapeutics's Enterprise Value
For the Biotechnology subindustry, Akebia Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Enterprise Value falls into.
Akebia Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Akebia Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Akebia Therapeutics's current Enterprise Value is €251.9 Mil.
Akebia Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.4 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Akebia Therapeutics's current Enterprise Value is €251.9 Mil.
Akebia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.3 Mil.
Akebia Therapeutics's current Enterprise Value is €251.9 Mil.
Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €173.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics (FRA:AX9) Business Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AX9 has been successfully added to your 